Meta-analysis: Antiviral treatment for hepatitis D

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 6, 2012, Pages 663-673

  Triantos, C ^a   Kalafateli, M ^a   Nikolopoulou, V ^a   Burroughs, A ^b  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2C INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; DELTA AGENT HEPATITIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; LIVER CIRRHOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; HEPATITIS D; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84857362586     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.04993.x     Document Type: Article

References (48)

1. Bonino F, Negro F, Baldi M, et;al. The natural history of chronic delta hepatitis. Prog Clin Biol Res 1987; 234: 145-52.
2. Hadziyannis SJ, Papaioannou C, Alexopoulou A,. The role of the hepatitis delta virus in acute hepatitis and in chronic liver disease in Greece. Prog Clin Biol Res 1991; 364: 51-62.
3. Romeo R, Del Ninno E, Rumi M, et;al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136: 1629-38.
4. Su CW, Huang YH, Huo TI, et;al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006; 130: 1625-35.
5. Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL,. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci USA 1993; 90: 9016-20.
6. Wu JC, Choo KB, Chen CM, et;al. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet 1995; 346: 939-41.
7. Hughes SA, Wedemeyer H, Harrison PM,. Hepatitis delta virus. Lancet 2011; 378: 73-85.
8. Farci P, Mandas A, Coiana A, et;al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330: 88-94.
9. Gaudin JL, Faure P, Godinot H, Gerard F, Trepo C,. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2b. Results of a randomized controlled trial. Liver 1995; 15: 45-52.
10. Erhardt A, Gerlich W, Starke C, et;al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006; 26: 805-10.
11. Madejon A, Cotonat T, Bartolome J, Castillo I, Carreno V,. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology 1994; 19: 1331-6.
12. Farci P, Roskams T, Chessa L, et;al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126: 1740-9.
13. Rosina F, Pintus C, Meschievitz C, Rizzetto M,. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991; 13: 1052.
14. Niro GA, Ciancio A, Gaeta GB, et;al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44: 713-20.
15. Castelnau C, Le Gal F, Ripault MP, et;al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44: 728-35.
16. Wedemeyer H, Yurdaydin C, Dalekos G, et;al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-31.
17. Lau DT, Doo E, Park Y, et;al. Lamivudine for chronic delta hepatitis. Hepatology 1999; 30: 546-9.
18. Yurdaydin C, Wedemeyer H, Dalekos G, et;al. A multicenter randomized study comparing the efficacy of pegylated interferon-alpha-2a plus adevofir dipivoxil vs. pegylated interferon-alpha-2a plus placebo vs. adevofir dipivoxil for the treatment of chronic delta hepatitis: the hep-net/international delta hepatitis intervention trial (HID-IT) (abstract). Hepatology 2006; 44 (Suppl. 1): 230A.
19. Yurdaydin C, Bozkaya H, Gurel S, et;al. Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002; 37: 266-71.
20. Wolters LM, Van Nunen AB, Honkoop P, et;al. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 2000; 7: 428-34.
21. Yurdaydin C, Bozkaya H, Onder FO, et;al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine;+;interferon vs interferon. J Viral Hepat 2008; 15: 314-21.
22. Niro GA, Ciancio A, Tillman HL, et;al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005; 22: 227-32.
23. Onder FO, Yakut M, Idilman R, et;al. Entecavir may be beneficial in a subset of patients with chronic delta hepatitis (abstract). Hepatology 2009; 50 (Suppl. 4): 735A.
24. Buti M, Lopez-Talavera JC, Allende H, Jardi R, Esteban R, Guardia J,. Serological diagnosis of chronic delta infection: correlation between serological markers and hepatitis delta virus RNA in hepatic tissue. Prog Clin Biol Res 1993; 382: 319.
25. Garripoli A, Di Marco V, Cozzolongo R, et;al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver 1994; 14: 154.
26. Kjaergard LL, Villumsen J, Gluud C,. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982-9.
27. Moher D, Cook DJ, Jadad AR, et;al. Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol Assess 1999; 3: 1-98.
28. Laupacis A, Sackett DL, Roberts RS,. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318: 1728-33.
29. Yusuf S, Peto R, Lewis J, Collins R, Sleight P,. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.
30. Klein J, Simes G, Blackburn L,. Total parenteral nutrition and cancer clinical trial. Cancer 1986; 58: 1378-86.
31. Leandro G,. Meta-analysis in Medical Research. Oxford, UK: Blackwell Publishing Ltd, 2004.
32. Gunsar F, Akarca US, Ersoz G, et;al. Two year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 2005; 10: 721-6.
33. Porres JC, Carreno V, Bartolome J, Moreno A, Galiana F, Quiroga JA,. Treatment of chronic delta infection with recombinant human interferon alpha 2c at high doses. J Hepatol 1989; 9: 338-44.
34. Borghesio E, Rosina F, Di Marco V, et;al. Long-term treatment of chronic hepatitis D with lymphoblastoid interferon-10 MU vs 5 MU-An interim report of a randomised controlled trial. Hepatology 1995; 22: 1161.
35. Rosina F, Saracco G, Lattore V, Quartarone V, Rizzeto M, Verme G, et;al. Alpha 2 recombinant interferon in the treatment of chronic hepatitis delta virus (HDV). Prog Clin Biol Res 1987; 234: 299-303.
36. Canbakan B, Senturk H, Tabak F, et;al. Efficacy of interferon a-2b and lamivudine combination treatment in comparison to interferon a-2b alone in chronic delta hepatitis: A randomized trial. J Hepatol Gastroenterol 2006; 21: 657-63.
37. Malaguarnera M, Restuccia S, Pistone G, Ruello P, Giugno I, Trovato B,. Meta-analysis of interferon-a treatment of hepatitis D virus infection. Pharmacotherapy 1996; 16: 609-14.
38. Di Marco V, Giacchino R, Timitilli A, et;al. Long-term interferon-alfa treatment of children with chronic hepatitis delta: a multicentre study. J Viral Hepat 1996; 3: 123-8.
39. Yurdaydin C, Bozkaya H, Karaaslan H, et;al. A pilot study of two years of interferon in patients with chronic delta hepatitis. J Viral Hepat 2007; 14: 812-6.
40. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL,. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-7.
41. Lutz HH, Trautwein C,. Reviving pegylated interferon as a therapeutic agent for hepatitis D: No more room for nucleos(t)ides? Hepatology 2011; 53: 2131-3.
42. Marzano A, Ottobrelli A, Spezia C, Daziano E, Soranzo ML, Rizzetto M,. Treatment of early chronic delta hepatitis with lymphoblastoid alpha interferon: a pilot study. Ital J Gastroenterol 1992; 24: 119-21.
43. Hughes S, Carey I, Shang D, et;al. Hepatitis delta virus RNA level and IgM antibody titer predict response to Peg-interferon therapy (abstract). Hepatology 2009; 50 (Suppl. 4): 735A.
44. Yurdaydin C, Kabacam G, Cakaloglu Y, et;al. Efficacy of pegylated interferon-based treatment in patients with cirrhosis due to chronic delta hepatitis: comparison with non-cirrhotic patients (abstract). Hepatology 2009; 50 (Suppl. 4): 736A.
45. Kau A, Vermehren J, Sarrazin C,. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634-51.
46. Glenn JS, Marsters JC Jr, Greenberg HB,. Use of a prenylation inhibitor as a novel antiviral agent. J Virol 1998; 72: 9303-6.
47. Bordier BB, Marion PL, Ohashi K, et;al. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol 2002; 76: 10465-72.
48. Bordier BB, Ohkanda J, Liu P, et;al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003; 112: 407-14.